CXCL8 and chronic obstructive pulmonary disease: A smaller placebo-controlled trial in COPD participants with persistent neutrophilic bronchitis demonstrated a clinically significant reduction in severe exacerbations, with non-significant trends toward decreases in sputum neutrophil proportion, CXCL8 concentration, and bacterial load [99].